Regulations only work in improving the well-being of the single market if the local producers can remain competitive after implementation. There are a small number of regulations in the EU which have damaged local manufacturers without significant improvement in quality of life e.g the medical device regulation. I do not know enough about the ai regulation to understand if it is for for purpose or not however.
Given the "free for all" other countries appear to be giving their AI systems, the EU may look to re-consider the ai regulation's implementation.
As far as I understand, the CCP has a central procurement system where it purchases a significant portion of the expected need for a drug in bulk each year. This "forces" the drug companies to offer a much lower price (or lose the sale to a competitor), allowing the medication to be provided cheaper to the people. Similar models exist in most countries with a form of centralised health care. In China however, there have been reports of close to break-even or loss prices for the manufacturers, leading to potential cutting of corners by the manufacturers.
Wouldn't capatilistic be allowing the companies to sell their drugs for a higher price to end users directly?